Activation of the signal transducer and activator of transcription 3 pathway Up-regulates estrogen receptor-β expression in lung adenocarcinoma cells

Molecular Endocrinology

Volumn 25, Issue 7, 2011, Pages 1145-1158

  Wang, Hao Chen ^a   Yeh, Hsuan Heng ^b   Huang, Wei Lun ^a,b   Lin, Chien Chung ^a,b   Su, Wen Pin ^a,b   Chen, Helen H W ^a,b   Lai, Wu Wei ^b   Su, Wu Chou ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR BETA; INTERLEUKIN 6; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HORMONE BINDING; HUMAN; HUMAN CELL; LUCIFERASE REPORTER ASSAY; LUNG ADENOCARCINOMA; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MUTATION, MISSENSE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA STABILITY; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 79959815001     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0495     Document Type: Article

References (57)

1. Siegfried JM 2001 Women and lung cancer: does oestrogen play a role? Lancet Oncol 2:506-513
2. Lam WK, 2005 Lung cancer in Asian women-the environment and genes. Respirology 10:408-417
3. Ger LP, Liou SH, Shen CY, Kao SJ, Chen KT 1992 [Risk factors of lung cancer]. J Formos Med Assoc 91(Suppl 3):S222-S231
4. Xu X, Li B, Wang L 1994 Gender difference in smoking effects on adult pulmonary function. Eur Respir J 7:477-483
5. Zang EA, Wynder EL 1996 Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88:183-192
6. Subramanian J, Govindan R 2007 Lung cancer in never smokers: a review. J Clin Oncol 25:561-570
7. Taioli E, Wynder EL 1994 Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86:869-870
8. Liu Y, Inoue M, Sobue T, Tsugane S 2005 Reproductive factors, hormone use and the risk of lung cancer among middle-aged neversmoking Japanese women: a large-scale population-based cohort study. Int J Cancer 117:662-666
9. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296:1642-1644
10. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA 1997 Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258-4265
11. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870
12. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JA, Hayashi SI 2001 Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 285:340-347
13. Mollerup S, Jørgensen K, Berge G, Haugen A 2002 Expression of estrogen receptors α and β in human lung tissue and cell lines. Lung Cancer 37:153-159
14. Thuresson-Klein A, Moawad AH, Hedqvist P 1985 Estrogen stimulates formation of lamellar bodies and release of surfactant in the rat fetal lung. Am J Obstet Gynecol 151:506-514
15. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, Maggi A, Warner M, Gustafsson JA, Nord M 2003 Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 23:8542-8552
16. _/_) mice. Proc Natl Acad Sci USA 103:7165-7169
17. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M 2005 Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65:1598-1605
18. Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, Land SR, Srinivas H 2009 Estrogen receptor β functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 23: 146-156
19. Darnell Jr JE 1997 STATs and gene regulation. Science 277:1630-1635
20. Levy DE, Darnell Jr JE 2002 Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662
21. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC 2006 Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25:4300-4309
22. Gschwind A, Fischer OM, Ullrich A 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-370
23. Hynes NE, Lane HA 2005 ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
25. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
26. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311
27. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346
28. Shen H, Yuan Y, Sun J, Gao W, Shu YQ, 2010 Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 64:88-92
29. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM 2005 Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459-1470
30. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, Onitsuka T, Yasumoto K, 2009 Association between estrogen receptorbeta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27:411-417
31. Toh CK, Ahmad B, Soong R, Chuah KL, Tan SH, Hee SW, Leong SS, Tan EH, Lim WT 2010 Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol 5:17-22
32. Sordella R, Bell DW, Haber DA, Settleman J 2004 Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167
33. Hodge DR, Hurt EM, Farrar WL 2005 The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41:2502-2512
34. Spiotto MT, Chung TD 2000 STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42:88-98
35. Björnström L, Sjöberg M, 2002 Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16:2202-2214
36. Song L, Turkson J, Karras JG, Jove R, Haura EB 2003 Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22:4150-4165
37. Downward J, Parker P, Waterfield MD, 1984 Autophosphorylation sites on the epidermal growth factor receptor. Nature 311:483-485
38. Shao H, Cheng HY, Cook RG, Tweardy DJ 2003 Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63:3923-3930
39. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF 2006 Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25:1205-1215
40. Weigert C, Düfer M, Simon P, Debre E, Runge H, Brodbeck K, Häring HU, Schleicher ED 2007 Upregulation of IL-6 mRNA by IL-6 in skeletal muscle cells: role of IL-6 mRNA stabilization and Ca2_-dependent mechanisms. Am J Physiol Cell Physiol 293: C1139-C1147
41. Frasor J, Park K, Byers M, Telleria C, Kitamura T, Yu-Lee LY, Djiane J, Park-Sarge OK, Gibori G, 2001 Differential roles for signal transducers and activators of transcription 5a and 5b in PRL stimulation of ERα and ERβ transcription. Mol Endocrinol 15:2172-2181
42. Hatae J, Takami N, Lin H, Honda A, Inoue R 2009 17β-Estradiolinduced enhancement of estrogen receptor biosynthesis via MAPK pathway in mouse skeletal muscle myoblasts. J Physiol Sci 59:181-190
43. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
44. Pao W, Miller VA 2005 Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568
45. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK 2006 The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485-495
46. Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K 2011 Expression of estrogen receptor β predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI foradenocarcinoma of the lung. Lung Cancer 71:350-355
47. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA 2006 Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66:3162-3168
48. Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, Barry W, Crawford J, Nevins J, Potti A 2010 Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 303:535-543
49. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494
50. Bunone G, Briand PA, Miksicek RJ, Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
51. Tremblay A, Tremblay GB, Labrie F, Giguére V 1999 Ligandindependent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 3:513-519
52. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM 2002 Human non-small cell lung tumors and cells derived from normal lung express both estro-gen receptor α and β and show biological responses to estrogen. Cancer Res 62:2141-2150
53. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J 2005 Estrogen receptor α and β are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11: 5084-5089
54. Márquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ 2007 Estrogen receptor signaling pathways in human nonsmall cell lung cancer. Steroids 72:135-143
55. Wu CT, Chang YL, Shih JY, Lee YC 2005 The significance of estrogen receptor _ in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130:979-986
56. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S 2005 Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin Cancer Res 11:7280-7287
57. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J 2007 Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104:7391-7396